Tomorrow's Catalysis
for Research and Industry

Beilstein Organic Chemistry Symposium 2017

24 – 26 October 2017
avendi Hotel am Griebnitzsee, Potsdam, Germany

Scientific Program:
Karol Grela / Institute of Organic Chemistry, Polish Academy of Sciences,
and University of Warsaw, Poland

Anna Kajetanowicz / University of Warsaw, Poland

The symposium has been inspired by the Thematic Series “Progress in metathesis chemistry II” in the Open Access Beilstein Journal of Organic Chemistry, edited by Karol Grela.

Catalysis represents an important discipline of chemistry, since it offers a number of widely recognized benefits — catalysed reactions can be mediated under mild conditions, proceeding with high conversion and selectivity. This allows even complicated products to be obtained in high yield without by-products and with little waste. Thus, properly optimised catalysed reactions can fulfil the requirements for “green” chemical production. New goals for catalysis are constantly being identified, including the sustainable production of valuable chemicals from renewable sources. Immobilisation of catalysts is another important aspect, as the supported catalysts can not only be more easily separated from the desired product but also reused several times, thus reducing the cost of the chemical process. Immobilised catalysts can also offer some unexpected advantages, such as increased selectivity and stability. The importance of these developments is now widely appreciated and more and more exciting results are to be expected from collaboration between academic and industrial scientists.

Program

TUESDAY, 24 OCTOber

Important asymmetric and catalytic transformations for drug development
Chris Senanayake / Boehringer Ingelheim Pharmaceuticals, USA

New ligands in Ir-catalyzed asymmetric allylic substitution reactions
Shu-Li You / Shanghai Institute of Organic Chemistry, China

Development of a long term manufacturing route to HCV NS5b inhibitor, MK-3682
John Limanto / Merck Research Laboratories, USA

Metal catalyzed or transition metal free arylation of nucleophiles: recent progress, industrial applications and mechanistic insight
Marc Taillefer / CNRS/ENSCM, Montpellier, France

New catalysts for olefin metathesis
Krzysztof Skowerski / Apeiron Synthesis, Poland

Oxidation-induced C–H activation and oxidative cross-coupling
Aiwen Lei / Wuhan University, China

Key technical challenges for industrial implementation of metathesis and hydroformylation in high value monomer synthesis
Jean-Luc Dubois / Arkema France

Selectivity control in C-H activation
Lutz Ackermann / University of Göttingen, Germany

WEDNESDAY, 25 october

Advances in cross-coupling catalysis
Michael Organ / University of Ottawa, Canada

New synthesis of C-glycosides via C-C coupling: catalyzed or uncatalyzed?
Vittorio Farina / Janssen Pharmaceutica, Belgium

Design of sustainable catalytic reactions based on metal-ligand cooperation
David Milstein / Weizmann Institute of Science, Rehovot, Israel

Development of challenging catalytic processes through mechanistic understanding
Yi Hsiao / Bristol-Myers Squibb, USA

THURSDAY, 26 OCTOber

Throwing light on organocatalysis: new opportunities in enantioselective synthesis
Paolo Melchiorre / Institute of Chemical Research of Catalonia, Tarragona, Spain

Photocatalysis for steroid synthesis
Stephen Bell / Almac Sciences, UK

Catalysis in flow – is heterogeneous or homogeneous the way to go?
C. Oliver Kappe / University of Graz, Austria

A combined high-throughput and mechanistic approach toward the synthesis of active pharmaceutical ingredients
David Leitch / GlaxoSmithKline, USA

Amide hydrogenation to amines - the toughest nut to crack
David Cole-Hamilton / University of St. Andrews, UK

Latest developments in catalytic hydrogenation
Laurent Lefort / Innosyn, The Netherlands

Homogeneous hydrogenation. An indispensable tool in the conversion of renewables and platform chemicals
Johannes de Vries / Leibniz Institute for Catalysis, Rostock, Germany

Enabling pharmaceutical development with novel catalytic transformations
Steven Mennen / Amgen, USA